viewCircassia Group PLC

Circassia Pharmaceuticals makes strong start to new financial year

The company said first-quarter sales were up 38%. The current trading update was contained in the company's annual results

lung via x-ray
The business focuses on respiratory products

Respiratory specialist Circassia Pharmaceuticals PLC (LON:CIR) said it made a strong start to 2019 with revenues up 38% year on year.

Annual results, meanwhile, charted a period of consolidation and operational progress.

It has taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while sales of its asthma product NIOX continued to grow.

Circassia has also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.

Financially, the company is well endowed. It had £40.7mln of cash at the end of 2018 with AstraZeneca subscribing just over £20mln to the firm’s share sale.

Sales growth 

Last year, Circassia saw its sales grow by 5% to £27.4mln with China, where there was de-stocking and a move to a direct sales operation, exerting the drag.

As is common with companies at this formative phase of their commercial development, the business was loss-making. The loss on continuing operations was £25.9mln.

“We made good progress in 2018 completing our strategic transition into a commercially-focused specialty pharmaceutical business focused on respiratory disease,” said chief executive Steven Harris.

“Our revenues continued to grow and we maintained our commercial investment and broad cost control activities. As a result, we dramatically reduced our net cash outflow and decreased the loss in our underlying business."

Looking ahead, he added: “We are making good progress building a robust business with growing revenue potential and an exciting commercial future."

Quick facts: Circassia Group PLC

Price: 24.2609 GBX

Market: LSE
Market Cap: £91.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read